Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
: Gonadotropin-releasing hormone (GnRH) antagonist protocols are preferred in polycystic ovary syndrome (PCOS) patients undergoing in vitro fertilization (IVF) as they provide the best combination of flexibility, acceptable outcomes, and safety. Numerous studies have compared outcomes between GnRH agonist long protocol and standard flexible antagonist protocol. However, there are scant studies investigating the effectiveness of antagonist administration from day 1 of ovarian stimulation in PCOS patients. : We performed a retrospective cohort study to compare laboratory and clinical outcomes in IVF between standard flexible day 5/day 6 versus day 1 GnRH antagonist protocol in PCOS patients. : Our data indicates significantly superior oocyte yield and top-quality embryo proportion in patients with antagonists from day 1. Cumulative clinical pregnancy rates also tended to be superior in this group. : Our findings indicate that administration of GnRH antagonists from day 1 of stimulation in PCOS patients undergoing IVF may lead to superior results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387123 | PMC |
| http://dx.doi.org/10.3390/jcm14165901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Comparison of live-birth rate after Freeze-All strategy between PCOS and non-PCOS patients].
Gynecol Obstet Fertil Senol
September 2025
Hospices Civils de Lyon, Hôpital Mère Enfant, Service de Médecine de la Reproduction, 59 boulevard Pinel, Bron, France; Université Claude Bernard, Faculté de Médecine Laennec, 7 rue Guillaume Paradin, Lyon, France; INSERM Unité 1208, 18 avenue Doyen Lépine, Bron, France; Université Claude B
Objective: Polycystic Ovarian Syndrome (PCOS) is a common pathology and the most frequent cause of infertility linked to dysovulation. These patients have a high ovarian reserve and, as a result, oocyte collection is often excessive. Following medically assisted reproduction techniques, i.
View Article and Find Full Text PDFUse of progestin-only drospirenone-based pills in hyperandrogenic women with polycystic ovary syndrome.
Arch Gynecol Obstet
September 2025
Department of Women's and Children's Health Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.Go Agostino Gemelli, 8, 00168, Rome, Italy.
Purpose: Polycystic ovarian syndrome (PCOS) is a common endocrine-metabolic disorder affecting about 10% of reproductive-age women. Characterized by hyperandrogenism and ovulatory dysfunction, PCOS often involves metabolic features due to insulin resistance. Traditional treatment with combined oral contraceptive pills (COCP) effectively manages hyperandrogenism and menstrual irregularities.
View Article and Find Full Text PDFPTTG1 as a common promising target for PCOS, Ovarian Cancer, and Major Depressive Disorder patients.
Comput Biol Chem
September 2025
Department of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Ranchi, India. Electronic address:
Women are susceptible to hormonal imbalances and endocrine-related disorders such as Polycystic Ovary Syndrome (PCOS), Ovarian Cancer (OC), and Major Depressive Disorder (MDD). This study aims to identify gene-level interconnections among these conditions using omics-based bioinformatic approaches. Publicly available GEO datasets, viz.
View Article and Find Full Text PDFEndometrial Carcinoma in a 26-Year-Old Obese Woman With Polycystic Ovary Syndrome: A Case Report.
Cureus
August 2025
Internal Medicine, Khwaja Yunus Ali Medical College, Sirajganj, BGD.
Endometrial carcinoma is one of the most common gynecologic cancers worldwide. The condition typically occurs after menopause; however, young women under the age of 40 years can also be diagnosed with the disease. Providers may delay diagnosis in young patients due to nonspecific presentation or low clinical suspicion.
View Article and Find Full Text PDFMyo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
JAMA
September 2025
Department of Obstetrics and Gynecology, Máxima Medical Center, Veldhoven, the Netherlands.
Importance: Pregnant individuals with polycystic ovary syndrome (PCOS) present with a higher risk of pregnancy complications, including gestational diabetes, preeclampsia, and preterm birth. Myo-inositol supplementation may reduce these risks.
Objective: To determine whether daily supplementation with myo-inositol during pregnancy among individuals with PCOS reduces the risk of a composite outcome of gestational diabetes, preeclampsia, and preterm birth.